A single-dose of Trogenix’s proprietary Synthetic Super-Enhancers achieved complete tumour elimination in 83% of treated cases with no toxicity over 11 months and no tumour…
Read More
Atif Abbas, MD joins as CMO, bringing over 25 years’ experience in oncology drug development and clinical and regulatory strategy Carolyn Edwards, PhD appointed VP,…
Read More
